Clinical Trial Update: A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation [Phase 3]

View source ↗

Summary

Phase 3 clinical trial updating the study of Fluzoparib with or without Apatinib versus chemotherapy in HER2-negative metastatic breast cancer patients with ger…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Apatinib (apatinib)
• Chemotherapy treatment of physician's choice
• Fluzoparib (fluzoparib)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation | Phase 3 | Status: UNKNOWN